DiogenX
Patrick Collombat has extensive work experience in the scientific field. Patrick is currently serving as a Scientific Advisor and co-Founder at DiogenX since January 2020. Prior to this, they worked at INSERM as a Team Leader since 2009. Patrick also gained valuable experience at the Max Planck Institute for Biophysical Chemistry, where they worked as a Postdoctoral Fellow from 1999 to 2009 and completed their PHD from 1999 to 2004.
Patrick Collombat attended Université Paul Sabatier Toulouse III. However, the specific years of their education, the degree obtained, and the field of study are not provided.
This person is not in any teams
This person is not in any offices
DiogenX
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patientswith diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.